It is well known that BRCA1 and BRCA2 mutations are one of the known risk determinants for the development of ovarian carcinoma and BRCA1/2 mutations is associated with response to platinum-based chemotherapy [3]. Here, BRCA1 is linked to ovarian carcinoma.